Data used to justify the expansion of controversial software in the NHS is flawed, experts say, and the pilot trust’s innovation adviser worked directly for Palantir
https://bit.ly/4stVolW
Cover of The Lancet's April 11, 2026 issue. Quote on cover reads: "Health cannot—and should not—be overlooked in the economies of war."
"Every 1% increase in military spending drives a 0·62% reduction in public health spending."
On the cover, a new letter examines the relationship between military spending and public health expenditure during conflicts.
Find out more in our latest issue: spkl.io/63325ANG6W
Some important messages in this 1 minute read.
Dr James Carpenter will present our new multi-parameter, wireless, vital sign monitoring for newborns to an audience of 90+ investors, strategics, clinicians, and industry leaders helping shape the future of medtech.
#MedTechInnovator #MTIRadarForum
Intriguing!
Shocking data.
Join us at the 17th Dresden Symposium on Feto-Neonatal Health & ESN Spring School under the leadership of ESPR Senior Member Prof Mario Rüdiger!📍 Dresden, 12-14 March.📅 Thu–Fri: cutting-edge talks; 🛠 Sat: hands-on workshops, incl. ESN NPE training. See the full programme here: tinyurl.com/3rhz4cuy
The next NeoTRIPs Lunch & Learn!
🧬 Clinical Genetics in Neonatal Medicine
🗓️ Friday 23rd January 12-2pm
🎟️ Register with your work email here:
neotrips.org/event/neotri...
@plos.org
journals.plos.org/digitalhealt... New paper out today from @tngchang.bsky.social from University of Nottingham with many collaborators (thanks). Excellent OA online extreme preterm mortality prediction tool with neat explainable element. Great for all perinatal teams.
🚀Calling all neonatal & paediatric researchers! Submit your abstract for #CEPAS2026 in Lyon (28–31 Oct) by 1 Apr 2026. Share your innovations, gain skills, and connect globally to shape the future of child health! www.cepas.org/abstracts?ut...
I've seen the published data on this which are worrying. I'm less convinced of the causal suggestion but certainly more work could tease thar out. Having a plastic tube in your trachea/bloodstream/GI tract for months may not be without hidden issues.
Our BiB trial manuscript now published in JAMA...Early Intratracheal Budesonide for Bronchopulmonary Dysplasia url: jamanetwork.com/journals/jam...
Our September newsletter is now available!
Read this month's issue here for news, upcoming events, funding opportunities and recent publications in child health 👉 mailchi.mp/d56096f82afc...
Editorial "Under an administration that says it is focused on making America healthy again, why are we denigrating and discarding our single most cost-effective public health tools?" "Risk and Benefit" by Eric J. Rubin, M.D., Ph.D.
Editor-in-Chief Eric Rubin asks why, under an administration that says it is focused on making America healthy again, we are denigrating and discarding our single most cost-effective public health tools — vaccines. Read the full editorial: nej.md/4mtH8Xm
#MedSky #PublicHealth
Sad to see this come to fruition. @stefanjohansson.nicuverse.org.ap.brid.gy your analysis gets a mention but despite the strengths it is dismissed...😔
Great to see neonatal studies of this type being published in JAMA.
Very thorough review and highlights early challenges FGR infants need to overcome. As highlighted, tricky to identify who truly is FGR vs constitutionally small.
Early days but a promising approach. Likely to be more challenging in my population of newborn infants but would be great to explore....
Interesting approach.
The link doesn't work
Some great baseline data to see how RSV prophylaxis works out in coming years.
Very nice. Agree, neonatology should not follow the historical approach of "one size fits all", we moved past that long ago and need to personalise treatments for the infant in front of us.
You can't beat some baby feet to grab your attention and make you read!
I've listened to almost all of these and they are great. Chatting about neonatal research and care. Well worth a listen for all involved in the care of newborns. Good work Mario and @espr-esn.bsky.social
Really interesting study pushing the boundaries on this tricky and often poor outcome condition. Perhaps a condition that one day will have a handful of centres with expertise to treat and hopefully improve outcomes.
The win ratio method is gaining traction in #RCTs. Is it just a trend or a smarter way to look at composite hierarchical outcomes? We break it down in our latest Stats, STAT!📊 in NEJM Evidence. youtube.com/watch?v=jKtF... #stats @nejm.org @sarahgorey.bsky.social @chardin.bsky.social @ai.nejm.org
A graph showing the crude cumulative incidence of malaria infection in the 6 months after the start of three monthly rounds of mass administration of ivermectin at a dose of 400 μg per kilogram of body weight, as compared with albendazole at a dose of 400 mg.
Ivermectin is an antiparasitic drug that kills mosquitoes feeding on treated persons. In this trial in Kenya, ivermectin given once per month for 3 months led to a 26% lower incidence of malaria than albendazole. Full trial results: nej.md/4lIyNzB
#MedSky #IDSky
Not convinced this is the answer to this problem.
